- 1 Colonization of intervertebral discs by Cutibacterium
- 2 acnes in patients with low back pain: protocol for an
- 3 analytical study with microbiological, phenotypic,
- 4 genotypic, and multiomic techniques
- 5 Vinícius Magno da Rocha¹, Carla Ormundo Gonçalves Ximenes Lima², Eliane de
- 6 Oliveira Ferreira²; Gabriel Corrêa de Farias³; Fábio César Sousa Nogueira⁴; Luis
- 7 Caetano Martha Antunes⁵; Keila Mara Cassiano⁶; Rossano Kepler Alvim Fiorelli¹
- ¹Departamento de Cirurgia geral e especializada, Escola de Medicina, Universidade
- 9 Federal do Estado do Rio de Janeiro (UniRio), Rio de Janeiro- RJ, Brazil; ²
- 10 Departamento de Microbiologia Médica, Institito de Microbiologia Paulo de Góes,
- 11 Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro-RJ, Brazil;
- 12 ³Departamento de Biologia Celular e Molecular, Fundação Oswaldo Cruz, Rio de
- Janeiro RJ, Brazil; ⁴Instituto de Química, Universidade Federal do Rio de Janeiro
- 14 (UFRJ), Rio de Janeiro-RJ, Brazil; ⁵Centro de Desenvolvimento Tecnológico em
- 15 Saúde, Fundação Oswaldo Cruz, Rio de Janeiro RJ, Brazil; ⁶Departamento de
- 16 Estatística, Instituto de Matemática, Universidade Federal Fluminense (UFF), Niterói-
- 17 RJ, Brazil;
- 18 Correspondig author: Eliane de Oliveira Ferreira, Av. Carlos Chagas Filho, 373,
- 19 CCS, Bloco I, 2 andar, Laboratório de Biologia de Anaeróbios, Departamento de
- 20 Microbiologia Médica, UFRJ, Rio de Janeiro-RJ, Brasil. E-mail:
- 21 eliane ferreirarj@micro.ufrj.br
- 22 **Keywords:** Intervertebral discs; *Cutibacterium acnes*; low back pain; analytical study;
- 23 multiomic techniques.

 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

24

25 26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Lumbar disc degeneration (LDD) and low back pain (LBP) are two conditions that are closely related. Several studies have shown Cutibacterium acnes colonization of degenerated discs, but whether and how these finding correlates with LBP is unknown. A prospective study was planned to identify molecules present in lumbar intervertebral discs (LLIVD) colonized by C. acnes in patients with LDD and LBP and correlate them with their clinical, radiological, and demographic profiles. The clinical manifestations, risk factors, and demographic characteristics of participants undergoing surgical microdiscectomy will be tracked. Samples will be isolated and pathogens found in LLIVD will be characterized phenotypically and genotypically. Whole genome sequencing (WGS) of isolated species will be used to phylotype and detect genes associated with virulence, resistance, and oxidative stress. Multiomic analyses of LLIVD colonized and non-colonized will be carried out to explain not only the pathogen's role in LDD, but also its involvement in the pathophysiology of LBP. This study was approved by the Institutional Review Board (CAAE 50077521.0.0000.5258). All patients who agree to participate in the study will sign an informed consent form. Regardless of the study's findings, the results will be published in a peer-reviewed medical journal. Trials registration number NCT05090553; preresults.

Introduction

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

LBP is a common complaint in the general population, and its incidence is about five times higher in patients with LDD and Modic endplate changes.(1,2) The link between these findings and the isolation of low virulence pathogens in LIVD has already been described in several studies, generating a lot of interest in the topic and promoting the bacterial hypothesis of LDD.(3–14) Albert et al. reported 46% of positive cultures for anaerobes in 61 patients undergoing lumbar discectomy, of which 80% had Modic type 1 changes.(15) Other studies corroborate these findings, with high identification rates for Cutibacterium acnes, an anaerobic and aerotolerant pathogen that is bacillus-shaped, stained by the Gram method, pleomorphic, non-spore-forming, and a biofilm producer.(11,16–20) Rollason et al. isolated strains of this bacterium from the LIVD of 64 patients, revealing the presence of genotypic profiles distinct from those found in the skin, suggesting that specific variants would be related to LBP.(21) Other authors believe that the presence of this pathogen in the LIVD of asymptomatic patients is due to contamination of the specimens during sampling and/or sample treatment in the laboratory environment. Carricajo et al. found positive cultures for C. acnes in only 3.4% of the discs from 54 patients, defending the possibility of contamination.(22) Rigal et al. also analyzed LIVD from 313 patients who underwent video-assisted retroperitoneal discectomy, with positive cultures for only six patients.(23) These marked divergences in microbiological results cast doubt on the bacterial hypothesis of LDD and, consequently, raise questions about the possibility of

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

anaerobic pathogens acting as triggers or amplifiers of LBP. Urguhart et al. conducted a systematic review of the literature on the subject and concluded that there is evidence correlating the *C. acnes* isolation with Modic type 1 changes and LBP, but there is a lack of studies producing substantial and irrefutable evidence. (24) Despite the fact that considerable effort has already been expended in determining the presence of *C. acnes* in LIVD, there are still no standard isolation protocols for this pathogen from this clinical specimen. Furthermore, prior to the preparation of this manuscript, studies have shown no consistency in the collection and analysis techniques used, making comparison and reproducibility of results difficult. Aware of this reality, Astur et al. proposed a protocol for a cohort study to identify C. acnes from intervertebral discs.(25) Although valid, the initiative has two significant limitations that should be highlighted. First, after collecting clinical specimens, their immediate inoculation in a liquid medium is not foreseen in the operating room, which increases the contact time of the samples with the aerobic environment and reduces the chances of microorganism recovery even with culture-specific techniques. Second, the authors also highlight sonication (ultrasound waves to release bacteria from the biofilm of surgical prostheses) of specimens for subsequent inoculation in automated blood culture vials; however, this technique was originally described for pathogen recovery from orthopedic prostheses rather than biological tissue(26) and, because the sonication parameters used are not clear (time, power, and frequency), the reproduction of results by other authors and the validation of this protocol is compromised.

Specific microbiological identification techniques, such as immediate inoculation of specimens in liquid culture medium while still in the operating room, vortex¹ for sessile cell recovery, incubation time extension in an anaerobic atmosphere with replication every 72 h, and the use of Matrix-Assisted Laser Desorption Ionization Time of Flight Mass spectrometry - MALDI-TOF MS (Bruker Coorporation), and multiplex-touchdown PCR² are strategies that assure reliable results regarding the presence of bacteria in intervertebral discs (27,28), but they do not explain the pathways through which these microorganisms would participate in LDD and/or LBP.

Once LIVD colonization by *C. acnes* is confirmed using microbiological techniques, in the absence of clinical signs of infection, the main challenge is to understand the implications of this finding for homeostasis of that microenvironment. Rajasekaran et al. showed strong evidence of LIVD colonization by *C. acnes* using rDNA-16s PCR and proteomic analyses (29). These authors discovered not only host defense proteins, but also proteins associated with bacterial viability and proliferation. Although these findings have demonstrated the active presence of *C. acnes* in intervertebral discs, definitively ruling out the possibility of contamination, they do not necessarily reflect the activity of the expressed proteins, which may remain inactive and without interference in pain-generating pathways and/or the inflammatory response.

In this context, the combined use of proteomic and metabolomic techniques to analyze LIVD colonized by *C. acnes* would be more appropriate in order to assess the subclinical consequences of the colonization by this pathogen.(30) These techniques have already been used successfully to define molecular signatures in other clinical settings,(31–34) especially in chronic pain,(35–40) and can also provide integrative information on cell function at the molecular level about the role of *C. acnes* in LDD and LBP.(41–44)

Hypotheses and objectives

108

109

110

111

112

113

114

115

126

128

129

- Our hypothesis is that LDD and LBP are related to LIVD colonization by *C. acnes*.
- The primary goal of this study is to determine the incidence of LIVD colonization by
- low virulent pathogens using specific sampling and culture techniques, as well as
- 119 phenotypic and genotypic techniques for microbiological characterization.
- Other objectives of the study include: 1- assessing the possibility of clinical specimen
- 121 contamination in positive cultures; 2- establishing a correlation between the presence
- of the pathogen and the clinical and radiological profile (Modic type 1 changes) of the
- study participants: 3- to outline a phylotypic profile of the most isolated *C. acnes* strains
- by bacterial WGS; and 4- identify a molecular profile for LDD and LBP in patients with
- positive cultures for *C. acnes* through proteomic and metabolomic techniques.

Justifications

127 Colonization of LIVD by *C. acnes* in patients with LDD supports the bacterial

hypothesis of LBP (4,8,29,45–47). The determination of a molecular profile for these

patients will not only contribute to a better understanding of the pathophysiological

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

basis of LBP associated with LDD (41-43), but it will also positively interfere in the clinical management of this common condition, rationalizing its treatment and optimizing its costs. Previously studies looked at small groups of patients and did not follow standardized sampling and analysis methods.(15.24.48.49) This makes it difficult to value these findings and while they do suggest a correlation between C. acnes and LBP, the evidence is insufficient to explain how this bacterium could be involved in the process of LIVD degeneration and generation/amplification of LBP. This is the first protocol to investigate the role of *C. acnes* in LIVD degeneration, combining isolation with culture techniques. phenotypic and characterization techniques; and genomic, proteomic, and metabolomic techniques. In addition, the protocol proposes the clinical-radiological characterization of the participants, blinding the researchers and controlling confounding variables, and following appropriate selection criteria and statistical planning to obtain significant results. **Methods and Analysis** This study protocol is registered with the Research Ethics Committee (REC) [CAAE: 50077521.0.0000.5258] of the Gaffrée and Guinle University Hospital (HUGG) and at Clinicaltrials.gov under NCT05090553 (https://clinicaltrials.gov/ct2/results?term=NCT05090553).

Study Design

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

This analytical study will be performed at a single location (Spine Surgery Center of

São Matheus Hospital (HSM) in collaboration with the Gaffrée Guinle University

Hospital (HUGG) and Anaerobic Biology Laboratory of Paulo de Góes Microbiology

Institute of the Universidade Federal do Rio de Janeiro (UFRJ).

The analyses will be performed sequentially, according to the surgical procedures

carried out on the selected participants, taking 6 months after for their recruitment and

ending 6 months after the surgical treatment of the last patient. Data from participants

will be collected using a form designed specifically for this study.

Population

Participants included in the study must meet the selection criteria listed below.

Inclusion Criteria

The inclusion criteria for the study will be participants aged between 18 and 65 years; both sexes; complaint of low back pain lasting more than 3 months; magnetic resonance imaging findings of lumbar disc degeneration (LDD) performed less than 6 months before inclusion in the study; indication for open surgical treatment with isolated microdiscectomy or associated with lumbar arthrodesis; failure of conservative treatment for at least 6 weeks and/or progressive neurological deficit; agreement to follow all phases of the clinical investigation, having signed the informed consent form (ICF) for participation in the study.

Exclusion Criteria

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

The exclusion criteria for the study will be a history of open lumbar spine surgery at any stage of life; chemotherapy or pulse therapy with corticoids; immune deficiency; previous intradiscal therapies (nucleotomy or discography); previous endoscopic surgery; history of spinal infection treated with antibiotics in the 6 months prior to inclusion in the study; use of antibiotics in the 2 months prior to the surgical procedure; incomplete research inclusion form; refusal to participate and/or sign the ICF.

Patient and Public involvement

Participant eligibility will be evaluated by the study researchers through a clinical interview and imaging exams evaluation, according to the participants' interest and availability to participate in the study. If the patient agrees to take part in the study, the predetermined selection criteria will be used to evaluate them. The researchers will explain the details of the study and conduct a joint reading of the ICF. Questions about the study objectives, risks and benefits, stages, and research confidentiality will be answered. A patient will only participate upon signing the ICF at this stage of the research. A copy of this document will be given to the participant, another to the responsible researcher, and a third will be attached to the medical record. After signing the consent form, the patient will undergo an evaluation for demographic and clinical data collection and the forms developed for this purpose will be completed. If the patient is unable to read and sign the written consent form, researchers will verbally explain the study details and the patient will orally provide consent in the presence of a witness who will sign the consent form. The recruitment of participants will take place over a 6-month period, until 120 individuals are included, aiming at a minimum number of 96 collections.

Participant Allocation

The participants will be operated by the same surgical team, and the surgical technique will be posterior discectomy followed by arthrodesis of the approached

segment.

Blinding

The results of microbiological cultures or molecular analysis will not be disclosed neither to the patients nor to the surgeons. The radiologist who will review the imaging tests will also be blinded to patient data and laboratory results. The researcher who

will be analyzing the pain and function scores will be blinded as well.

Withdrawal of a Study Participant

A participant will be removed from the study in cases of ICF withdrawal, death, recruitment failure identification, loss of post-surgical follow-up, or the presentation of clinical symptoms of infection, intense pain, fever without other infectious *foci*, increased erythrocyte sedimentation rate and/or C-reactive protein, leukocytosis, imaging tests compatible with spondylodiscitis, or any other condition that leads to blinding interruption.

The reason and circumstances of each participant's withdrawal from the study will be detailed. The data gathered until the patient is withdrawn from the study will be included in the final analysis.

Selection of Outcomes

Primary Outcome

The main objective of this study will be to determine the incidence of intervertebral disc colonization by *C. acnes* in patients with LBP and LDD. Positive cultures will be used to confirm colonization, followed by phenotypic and genotypic confirmation of the isolated pathogen by mass spectrometry (Biotyper) and rDNA-16s PCR analysis, respectively.

Secondary Outcomes

Low back pain

At the time of patient recruitment the Visual Numeric Scale (VNS)(50) will be used to assess LBP intensity and daily activity limitations. A 30% increase in baseline LBP in the first postoperative month will be considered clinically significant. The VNS and the visual analogue scale have a good correlation and are equally sensitive to quantifying postoperative pain.(51)

Quality of life

The validated Portuguese version of the EuroQol questionnaire (EQ-5D) will be used to assess the quality of life of colonized and non-colonized groups with and without Modic changes.(52) The EQ-5D is a self-administrated standardized instrument containing five items (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).

Functionality

The functionality of the participants will be quantified through the validated Portuguese version of the Oswestry Disability Index (ODI) for LBP.(53)

Host multiomic characteristics

237

238

239

240

241

242

243

244

245

246

247

250

251

258

Proteomic and metabolomic techniques will be used to examine disc and plasma samples. The comparison of the group of molecules found in disc and plasma samples may contribute to the quantitative and qualitative identification of profiles using peripheral blood that are associated with the presence of the pathogen in the intervertebral disc. After processing the multiomic raw data using proper bioinformatics tools, statistical techniques will be applied to analyze them against the clinical-radiological and microbiological profiles of the participants. We expect to provide a molecular signature relating the presence of *C. acnes*, LDD and LBP.

Adverse Effects

- Failures related to surgical treatment, such as surgical wound infection, CSF leak,
- 248 deep vein thrombosis, pain recurrence, or any other adverse events that may arise in
- 249 the postoperative period, will be reported and considered in data analysis.

Sampling

- The Schedule of enrolment, Interventions, and assessments is shown in Fig. 1. During
- 252 anesthetic induction, intravenous antibiotic prophylaxis will be administered after
- 253 patient admission to the operating room. Cefazolin at a dose of 1 g replicated every 4
- 254 h for the duration of the surgery will be used as an antimicrobial drug. The antibiotic
- 255 prophylaxis regimen will end with skin closure and will not be extended for additional
- 256 postoperative time (Fig 2).
- This is the legend of Fig 2. Flowchart showing all stages of the study.

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

The clinical specimens collected will be: 1. Peripheral blood. A 10 mL aliquot will be obtained 30 min after the infusion of surgical antibiotic prophylaxis through upper limb venoclysis. This sample will be placed in a tube containing clot activator for further separation of the serum, which, in turn, will be stored at -80°C for further analysis. 2. Skin swab. After skin asepsis with 2% chlorhexidine gluconate degerming solution and 0.5% chlorhexidine gluconate alcoholic solution, a swab will be collected from the region where the surgical incision will be performed. 3. Intervertebral disc. Five fragments will be collected at each level approached during surgery. A set of sterile surgical tweezers will be used exclusively for collection, one for each tissue fragment collected. The forceps with tissue fragment will be given to a member of the laboratory who will monitor the procedure inside the operating room immediately after collection. Each fragment will be placed in a vial containing thioglycolate broth (Merck[®], Brazil) and 20 glass beads. The vials will be labeled with the initials of the study participants and the type of clinical specimen. After collection, the vials containing the clinical

specimens will be kept at room temperature (18°C to 22°C) and transported in a

specific case to the laboratory within a maximum period of 2 h.

4. Muscle-ligament tissue. Before obtaining the LIVD fragments, five fragments of muscle-ligament tissue adjacent to the collected disc will be collected. The same collection and initial cooling precautions used for the disc fragments will be followed when collecting the adjacent tissue.

Laboratory Analysis

Cultures

The skin swabs will be opened only in a laboratory setting. Samples will be seeded on blood agar plates (5% defibrinated sheep blood; blood agar base, 40 g/L; agar, 5 g/L) and anaerobic blood agar (5% defibrinated sheep blood; blood agar base, 40 g/L; agar, 5 g/L; hemin, 10 mL/L; menadione, 5 drops/L. After sowing in solid media, the swab will be inoculated in thioglycolate medium, where it will remain for 14 days. One of the plates will be incubated in a capnophilic atmosphere (5% to 10% CO_2), while the other will be incubated in strict anaerobiosis (atmosphere containing 10% CO_2 ,10% H_2 , and 80% N_2) using an anaerobic chamber or Glove Box (Coy Labs®, USA).

The plates will be read after 24 h of incubation and, in case of growth, the colonies will be identified. In the absence of growth, they will be incubated again, and a new reading will be performed after 72 h. The thioglycolate vials containing skin swabs will be kept in a bacteriological incubator (35°C to 37°C) for 14 days.

In a laboratory setting, the tubes containing disc fragments and muscle–ligament tissue will undergo vortexing (Even EVX2800-Bl®, Brazil) for 15 s. All tubes will be kept in a bacteriological incubator (35°C to 37°C) and, after 24 h, the first subculture will be carried out using a 100 µL bacteriological loop. An aliquot of the thioglycolate will be

taken and plated on blood agar and anaerobic blood agar. The first plate will be incubated in a capnophilic atmosphere and the second in strict anaerobiosis using an anaerobic chamber or Glove Box (Coy Labs®, USA). The plates will be read after 24 h and the colonies will be identified in case of growth. In the absence of growth, they will be incubated again, and a new reading will be performed after 72 h. The same procedure will be used for all thioglycolate vials (totaling six vials for each level approached). Thioglycolate tubes containing the clinical specimens will be kept in an oven for 14 days. Subcultures will be carried out after 72 h and always every 3 days, with the last subculture being carried out on the 14th day of incubation in the same solid culture medium and atmospheres used in the first 24 h.

Quality control of culture media

Sterile saline solution at 0.9% will be used to control the sterility of the culture medium and *Pseudomonas aeruginosa* ATCC 27853 and *Bacteroides fragilis* ATCC 25285 strains to evaluate the recovery capacity of facultative microorganisms and strict anaerobes. Each new batch of culture medium prepared will undergo this quality control.

Phenotypic characterization

The phenotypic identification of the species will be carried out through mass spectrometry using MALDI-TOF MS equipment (Bruker Biotyper®, Germany). The score used for reliable identification of pathogens will follow the manufacturer's instructions.

Genotypic characterization

The microorganisms isolated from cultures will be subjected to PCR analysis performed in two phases, as described by Bernard et al. (28) The first to confirm the presence of bacteria (target and non-target) by using species-specific primers targeting the rRNA-16s and a second one, Multiplex_PCR, targeting the virulence and oxidative gens.

Multiomic Analyses

Whole Genome Sequencing

For the WGS, the DNA of the isolated *C. acnes* strains will be obtained with the Qiagen

Blood & Tissue DNA extraction kit (Qiagen®, USA) and subsequent sample purification

using RNase.

The extracted and purified DNA will be dosed, and adjusted to a concentration of 0.2 ng/μL. The ends of its two ribbons will be fragmented and tagged (forward and reverse 5'--3'). This will form fragments of different sizes. This data will be used to create a database on the Nextera Flex Kit platform (Ilumina®, USA). The samples will then be multiplexed into a cell stream and run on the NextSeq sequencer (Ilumina®, USA) using paired sequencing to generate files in fastq format files, which will then be filtered using the Trimmomatic tool version 0.36, as recommended by Bolger et al.(54) This step will be critical for controlling the quality of the analysis because it reduces the possibility of errors during sequencing and allows the use of more reliable reading codes.

The obtained fragments will be sequenced, and their quality will be evaluated with the FastQC tool version 0.11.9. The RedDog software version 1.11 will be used to identify single nucleotide polymorphisms (SNPs) using the GCA 000008345.1 *C. acnes*

350

351

352

353

354

355

356

357 358

359

360

361

362

363

364

365

366 367

368

369

370

371

372

373

reference strain deposited in the GenBank NCBI [https://www.ncbi.nlm.nih.gov/nuccore/] as a comparison. Finally, the PATRIC software version 3.5.21 will be used to create a complete genome phylogeny from the concatenation of SNPs. **Proteomics** In this study, proteomics approaches will apply gel-free and in-gel protein digestion by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) technique and (2) Thioglycolate culture mediums will be centrifuged, and the sediment obtained will be washed in phosphate buffer and centrifuged again. The sediment will be dissolved in a lysis solution containing 8 M urea, 2% 3-[(3-cholamidopropyl) dimethylammonio]-1propanesulfonate, and 40 mM Tris (hydroxymethyl) aminomethane. This lysis will be complemented with the use of glass beads under a Bead Beater agitation (Biospec Product[®], USA) (3 × 20 s with intervals of 20 s) followed by cooling for 5 min on an ice bath, as described by Shah et al.(55) Protein concentration will be measured and 20 µg will be used for both the gel and solution techniques. The SDS-PAGE -based technique will be used to evaluate the profile of the proteins present in the extract. Proteins will be removed from the gel with a sterile scalpel, eluted, and trypsinized (proteolic digestion) for further analysis through mass spectrometry. In the solution technique, the obtained extract will be trypsinized for further analysis through mass spectrometer. Regardless of the technique used, a nano-Liquid Chromatography coupled to a high-resolution mass spectrometer (nLC-HRMS) will be used.

After analysis by both techniques, the raw data (.raw) will be converted into a mascot general file (.mgf) using the Mascot Distiller software version 2.8.0, and proteins will be identified using protein banks referring to *C. acnes* and eukaryotes (humans), both created using the NCBI as a fasta extension. After this identification, the data will be validated using the Scaffold software version 5 for the same databases. Two biological replicas will be made for both the gel and solution technique. The Interactivenn.net [http://www.interactivenn.net/index.html](56) and STRING version 11 software (57) will be used for comparative analysis and functional interaction of proteins, respectively.

Metabolomics

374 375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

The metabolomic analysis in this study will use intervertebral disc fragments with and without isolated *C. acnes*. The tubes containing the disc fragments in thioglycolate liquid culture medium will be centrifuged and the sediment will be transferred to 2 mL flat-bottom polypropylene tubes containing a titanium bead (one per tube). The liquid content of these tubes will be evaporated by centrifugation with the CentriVap SpeedVac apparatus (Labconco Corporation®, USA) and then weighed to determine the dry weight. The tubes will then have 500 µL of MS Grade (Fluka) acetonitrile added followed by Bead Beater agitation (Biospec Product®, USA) (4 x 30 s). When all the material has been dissolved, the tubes will be centrifuged, and the supernatant will be stored at -80°C in new sterile tubes. To identify the metabolites, the material will be injected into a high-resolution mass spectrometer (UHPLC Q-TOF MS/MS). The data obtained will be analyzed the Metaboanalyst 5.0 database in [https://www.metaboanalyst.ca/] and its functions and interactions in the STRING software version 11.(57)

Questionnaires

Questionnaires on pain (VNS), functionality (ODI), and quality of life (EQ-5D) will be given at recruitment as well as at 1, 3, and 6 months postoperatively. A professional who is not involved in the study will collect all questionaires. Follow-up clinical visits will be carried out at 1, 3, and 6 months postoperatively, with acceptance deviation of 7, 14, and 21 days, respectively.

Imaging Studies

Imaging studies include 1.5 T magnetic resonance imaging. The tests must be dated no later than 6 months prior to the participant's inclusion in the study. Any of the following changes will be considered disc degeneration: disc protrusion, extrusion, or sequestration; reduced disc intensity; annular ruptures; Schmorl's nodes (Depressions on the surface of the vertebral bodies identified on MRI scans that result from the pressure exerted by the intervertebral discs on the endplates, causing intervertebral disc tissue herniation and displacement into the adjacent vertebral bodies); Modic changes; and/or loss of disc height.

Modic Changes

The presence of Modic type 1 changes will be considered in the evaluation of magnetic resonance images. This change is characterized by the presence of a high signal on T2-weighted sequences, with reduced signal on T1-weighted sequences.(1,2) The frequency of Modic type 1 changes in the participants will be calculated for each of the research groups (presence or absence of colonization) and for the total number of discs analyzed in the laboratory.

Pfirrmann Classification

- 423 Degenerative changes identified in the discs will be categorized according to the
- 424 Pfirrmann classification(58) using T2-weighted magnetic resonance images.

Confounding Variables

- 426 As some of this information may change during the study, the data obtained at the
- 427 time of inclusion in the study will be considered. Below are the confounding variables
- 428 to be analyzed:
- 429 Age

422

425

434

438

439

440

442 443

444

445 446

447

448

449 450

451

452

453

454 455

456

- 430 Sex
- 431 Education
- 432 Leave of absence
- Alcohol consumption
 - 1. None or sporadically (< 1 dose/day)
- 435 2. Mild (1–2 doses/day)
- 436 3. Moderate/High (≥ 3 doses/day)
- 437 Smoking
 - 1. Non-smoker
 - 2. Smoker
 - 3. Ex-smoker
- Body mass index
 - 1. Underweight (< 18.5 Kg/m²)
 - 2. Normal (18.5–25 Kg/m²)
 - 3. Overweight (25-30 Kg/m²)
 - 4. Obese (> 30 Kg/m²)
 - Physical activity practice
 - 1. Sedentary (not performing physical activity for at least 10 continuous minutes during the week)
 - 2. Active (vigorous activities for three or more days/week and for 20 min or more per session; or moderate activity or walking for five or more days/week and for 30 min or more per session; or any activity added together 5 or more days/week and 150 min or more/week)
 - 3. Very active (vigorous activity for five or more days/week and 30 min or more per session; vigorous activity for three or more days/week and 20 min or more per session, more moderate activity and/or walking for five or more days/week and for 30 min or more per session)

- Use of oral steroids up to 3 months before surgery
- 458 Diabetes

Statistical planning

Sample size calculation

Considering the main outcome proposed, the identification of disc colonization by C. acnes, the minimum sample size (n) for the population of interest will be 96 participants, according to the calculation described by Medronho et al.,(59) using a

confidence interval of 95% and a maximum margin of error of 10%.

The ideal sample size for analysis of secondary outcomes will depend on the incidence of the main outcome. If it is too low, an increase in the number of patients included will be performed with the inclusion of more blocks of participants. In order to have a more accurate dimension, the sample size calculation will be revised as soon as we reach half of the initially planned sample size.

Statistical analysis methodology

The database will be analyzed using the SPSS software, version 22.0, and R software, version 4.0.2. Descriptive analysis will be performed by charts and descriptive statistics. The inferential analysis will consider a maximum significance level of 5%. The chi-square test or Fisher's exact test will be used for inferential analysis of the distributions of categorical variables. The odds ratio (OR) will be the measure used to estimate risk. The OR's significance will be evaluated by the OR's asymptotic confidence interval. The hypothesis of normality will be verified by the Kolmogorov–Smirnov and Shapiro–Wilk tests. Student's t-test or Mann-Whitney test will be used in the comparison of the two independent groups. More than two independent groups will be compared by the ANOVA or by the Kruskal–Wallis test. Two repeated measures in different assessments will be compared by the paired Student's t-test or by the

Wilcoxon's signed-rank test. More than two repeated measures will be compared by the ANOVA for repeated measures, or by the Friedman's test.

The identification of an optimal cutoff point for the marker associated with an outcome will be established through the analysis of the receiver operating characteristic (ROC) curve. The performance will be evaluated by the area under the ROC curve (AUC), and the significance of the AUC will be evaluated by the test that judges the null hypothesis that AUC is equal to 0.5. In addition to the significance test, the asymptotic confidence interval for the AUC will be obtained.

Analysis of the association between two quantitative variables will be visualized by scatter plots and quantified by the Pearson correlation coefficient, in the case of normal distributions, or by the Spearman's correlation coefficient, if normal distribution is not verified in at least one of the variables. The significance of the correlation coefficient will be evaluated by the correlation coefficient test.

Linear or non-linear regression models will be proposed to explain the relationship between the clinical—radiological variables of the patient and the quantitative outcome variables (colonization and multiomic profile). For the variable colonization (binary), logistic regression models will be proposed. Regression model parameters will be estimated by the maximum likelihood method, and the forward Wald method will be used to choose the variables. The goodness of fit of the model will be analyzed by adherence statistics, residual analysis, and verification of theoretical assumptions of the model.

Ethics and dissemination

The protocol will follow the ethical standards of the HUGG REC. All patients whose biological materials will be analyzed will be well-informed of the research objectives and will sign ICF, agreeing with the availability of samples for further laboratory analysis.

Acknowledgements

The authors gratefully acknowledge the Brazilian agencies Conselho Nacional de Desenvolvimento Científico e Tecnologico (CNPq), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001 for supporting this study.

Competing interests statement

The researchers declare no conflicts of interest.

Authors' contributions

VMR: conception and design of the work, data collection, data analysis and interpretation, and drafting the article. COGXL: conception and design of the work, data collection. EOF: conception and design of the work, data collection, data analysis and interpretation, critical revision of the article and final approval of the version to be published. GCF: electronic data storage. FCSN: data analysis and interpretation. LCMA: data analysis and interpretation. KMC: statistical design of the work, data analysis and interpretation. RKAF: critical revision of the article and final approval of the version to be published.

References

537

- 538 1. Modic MT, Masaryk TJ, Ross JS, Carter JR. Imaging of degenerative disk
- 539 disease. Radiology [Internet]. 10 de julho de 1988 [citado 25 de julho de 2021];
- Disponível em: https://pubs.rsna.org/doi/abs/10.1148/radiology.168.1.3289089.
- 541 2. Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR. Degenerative disk
- 542 disease: assessment of changes in vertebral body marrow with MR imaging.
- 543 Radiology. 10 de janeiro de 1988;166(1):193–9.
- 544 3. Tang G, Chen Y, Chen J, Wang Z, Jiang W. Higher proportion of low-virulence
- 545 anaerobic bacterial infection in young patients with intervertebral disc herniation. Exp
- 546 Ther Med. 2019/10/02 ed outubro de 2019;18(4):3085–9.
- 547 4. Capoor MN, Lochman J, McDowell A, Schmitz JE, Solansky M, Zapletalova M,
- 548 et al. Intervertebral disc penetration by antibiotics used prophylactically in spinal
- 549 surgery: implications for the current standards and treatment of disc infections. Eur
- 550 Spine J. 2018/12/07 ed abril de 2019;28(4):783–91.
- 551 5. Capoor MN, Ruzicka F, Machackova T, Jancalek R, Smrcka M, Schmitz JE, et
- 552 al. Prevalence of Propionibacterium acnes in Intervertebral Discs of Patients
- 553 Undergoing Lumbar Microdiscectomy: A Prospective Cross-Sectional Study. PLoS
- 554 One. 2016/08/19 ed 2016;11(8):e0161676.
- 555 6. Capoor MN, Konieczna A, McDowell A, Ruzicka F, Smrcka M, Jancalek R, et
- 556 al. Pro-Inflammatory and Neurotrophic Factor Responses of Cells Derived from
- 557 Degenerative Human Intervertebral Discs to the Opportunistic Pathogen
- 558 Cutibacterium acnes. Int J Mol Sci [Internet]. 2021/03/04 ed 26 de fevereiro de
- 559 2021;22(5). Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/33652921
- 560 7. Capoor MN, Ruzicka F, Schmitz JE, James GA, Machackova T, Jancalek R, et
- al. Propionibacterium acnes biofilm is present in intervertebral discs of patients
- undergoing microdiscectomy. PLoS One. 2017/04/04 ed 2017;12(4):e0174518.
- 563 8. Schmid B, Hausmann O, Hitzl W, Achermann Y, Wuertz-Kozak K. The Role of
- 564 Cutibacterium acnes in Intervertebral Disc Inflammation. Biomedicines [Internet].
- 565 2020/07/08 ed 30 de junho de 2020;8(7). Disponível em:
- 566 https://www.ncbi.nlm.nih.gov/pubmed/32629986
- 567 9. Nguyen HP, Zaroff JG, Bayman EO, Gelb AW, Todd MM, Hindman BJ, et al.
- 568 Perioperative hypothermia (33 degrees C) does not increase the occurrence of
- 569 cardiovascular events in patients undergoing cerebral aneurysm surgery; findings from
- 570 the Intraoperative Hypothermia for Aneurysm Surgery Trial. Anesthesiology. agosto
- 571 de 2010;113(2):327-42.

- 572 10. Li B, Dong Z, Wu Y, Zeng J, Zheng Q, Xiao B, et al. Association Between
- 573 Lumbar Disc Degeneration and Propionibacterium acnes Infection: Clinical Research
- and Preliminary Exploration of Animal Experiment. Spine Phila Pa 1976. 2015/12/15
- 575 ed 10 de julho de 2016;41(13):E764–9.
- 576 11. Yuan Y, Zhou Z, Jiao Y, Li C, Zheng Y, Lin Y, et al. Histological Identification
- 577 of Propionibacterium acnes in Nonpyogenic Degenerated Intervertebral Discs.
- 578 Biomed Res Int. 2017/04/13 ed 2017;2017:6192935.
- 579 12. Zheng Y, Lin Y, Chen Z, Jiao Y, Yuan Y, Li C, et al. Propionibacterium acnes
- induces intervertebral discs degeneration by increasing MMP-1 and inhibiting TIMP-1
- 581 expression via the NF-kappaB pathway. Int J Clin Exp Pathol. 2018/07/01 ed
- 582 2018;11(7):3445–53.
- 583 13. Zhou Z, Chen Z, Zheng Y, Cao P, Liang Y, Zhang X, et al. Relationship between
- annular tear and presence of Propionibacterium acnes in lumbar intervertebral disc.
- 585 Eur Spine J. 2015/08/20 ed novembro de 2015;24(11):2496–502.
- 586 14. Wang Y, Che M, Xin J, Zheng Z, Li J, Zhang S. The role of IL-1beta and TNF-
- 587 alpha in intervertebral disc degeneration. Biomed Pharmacother. 2020/08/28 ed
- 588 novembro de 2020;131:110660.
- 589 15. Albert HB, Sorensen JS, Christensen BS, Manniche C. Antibiotic treatment in
- 590 patients with chronic low back pain and vertebral bone edema (Modic type 1 changes):
- 591 a double-blind randomized clinical controlled trial of efficacy. Eur Spine J. abril de
- 592 2013;22(4):697–707.
- 593 16. Najafi S, Mahmoudi P, Bassampour SA, Shekarchi B, Soleimani M,
- 594 Mohammadimehr M. Molecular detection of Propionibacterium acnes in biopsy
- 595 samples of intervertebral disc with modic changes in patients undergoing herniated
- disc surgery. Iran J Microbiol. dezembro de 2020;12(6):516–21.
- 597 17. Salehpour F, Aghazadeh J, Mirzaei F, Ziaeii E, Alavi SAN. Propionibacterium
- 598 acnes Infection in Disc Material and Different Antibiotic Susceptibility in Patients With
- 599 Lumbar Disc Herniation. Int J Spine Surg. 2019/05/28 ed abril de 2019;13(2):146–52.
- 600 18. Arndt J, Charles YP, Koebel C, Bogorin I, Steib JP. Bacteriology of degenerated
- 601 lumbar intervertebral disks. J Spinal Disord Tech. 2012/07/27 ed outubro de
- 602 2012;25(7):E211-6.
- 603 19. Stirling A, Worthington T, Rafiq M, Lambert PA, Elliott TSJ. Association
- between sciatica and Propionibacterium acnes. The Lancet. 2001;357(9273):2024–5.

- 605 20. Jiao Y, Lin Y, Zheng Y, Yuan Y, Chen Z, Cao P. The bacteria-positive proportion
- in the disc tissue samples from surgery: a systematic review and meta-analysis. Eur
- 607 Spine J. 2019/07/18 ed dezembro de 2019;28(12):2941–50.
- 608 21. Rollason J, McDowell A, Albert HB, Barnard E, Worthington T, Hilton AC, et al.
- 609 Genotypic and antimicrobial characterisation of Propionibacterium acnes isolates from
- 610 surgically excised lumbar disc herniations. Biomed Res Int. 2013/09/26 ed
- 611 2013;2013:530382.
- 612 22. Carricajo A, Nuti C, Aubert E, Hatem O, Fonsale N, Mallaval FO, et al.
- Propionibacterium acnes contamination in lumbar disc surgery. J Hosp Infect. julho de
- 614 2007;66(3):275–7.
- 615 23. Rigal J, Thelen T, Byrne F, Cogniet A, Boissiere L, Aunoble S, et al. Prospective
- study using anterior approach did not show association between Modic 1 changes and
- 617 low grade infection in lumbar spine. Eur Spine J. 2016/01/29 ed abril de
- 618 2016;25(4):1000–5.
- 619 24. Urquhart DM, Zheng Y, Cheng AC, Rosenfeld JV, Chan P, Liew S, et al. Could
- low grade bacterial infection contribute to low back pain? A systematic review. BMC
- 621 Med. 2015/01/23 ed 22 de janeiro de 2015;13:13.
- 622 25. Astur N, Martins DE, Wajchenberg M, Ferretti M, Menezes FG, Doi AM, et al.
- 623 Subclinical Propionibacterium acnes infection estimation in the intervertebral disc
- 624 (SPInE-ID): protocol for a prospective cohort. BMJ Open. 2017/11/21 ed 17 de
- 625 novembro de 2017;7(11):e017930.
- 626 26. Evangelopoulos DS, Stathopoulos IP, Morassi GP, Koufos S, Albarni A,
- 627 Karampinas PK, et al. Sonication: A Valuable Technique for Diagnosis and Treatment
- of Periprosthetic Joint Infections. Sci World J. 10 de outubro de 2013;2013:e375140.
- 629 27. Suarez S, Nassif X, Ferroni A. [Applications of MALDI-TOF technology in
- clinical microbiology]. Pathol Biol (Paris). fevereiro de 2015;63(1):43–52.
- 631 28. Barnard E, Nagy I, Hunyadkurti J, Patrick S, McDowell A. Multiplex touchdown
- PCR for rapid typing of the opportunistic pathogen Propionibacterium acnes. J Clin
- 633 Microbiol. 2015/01/30 ed abril de 2015;53(4):1149–55.
- 634 29. Rajasekaran S, Tangavel C, Aiyer SN, Nayagam SM, Raveendran M, Demonte
- NL, et al. ISSLS PRIZE IN CLINICAL SCIENCE 2017: Is infection the possible initiator
- of disc disease? An insight from proteomic analysis. Eur Spine J. 2017/02/09 ed maio
- 637 de 2017;26(5):1384-400.

- 638 30. Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive
- 639 metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019/03/01 ed junho
- 640 de 2019;20(6):353–67.
- 641 31. Swank KR, Furness JE, Baker EA, Gehrke CK, Biebelhausen SP, Baker KC.
- 642 Metabolomic Profiling in the Characterization of Degenerative Bone and Joint
- Diseases. Metabolites [Internet]. 2020/06/04 ed 29 de maio de 2020;10(6). Disponível
- em: https://www.ncbi.nlm.nih.gov/pubmed/32485832
- 645 32. Ou J, Xiao M, Huang Y, Tu L, Chen Z, Cao S, et al. Serum Metabolomics
- 646 Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy. Front
- 647 Immunol. 2021/03/09 ed 2021;12:630791.
- 648 33. Fernandez-Garcia M, Rojo D, Rey-Stolle F, Garcia A, Barbas C. Metabolomic-
- 649 Based Methods in Diagnosis and Monitoring Infection Progression. Exp Suppl.
- 650 2018/12/12 ed 2018;109:283-315.
- 651 34. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and
- 652 towards mechanisms. Nat Rev Mol Cell Biol. 2016/03/17 ed julho de 2016;17(7):451-
- 653 9.
- 654 35. Shan L, Yang J, Meng S, Ruan H, Zhou L, Ye F, et al. Urine Metabolomics
- Profiling of Lumbar Disc Herniation and its Traditional Chinese Medicine Subtypes in
- Patients Through Gas Chromatography Coupled With Mass Spectrometry. Front Mol
- 657 Biosci. 2021/06/29 ed 2021;8:648823.
- 658 36. Teckchandani S, Nagana Gowda GA, Raftery D, Curatolo M. Metabolomics in
- 659 chronic pain research. Eur J Pain. 2020/10/17 ed fevereiro de 2021;25(2):313–26.
- 660 37. Liu M, Xie Z, Costello CA, Zhang W, Chen L, Qi D, et al. Metabolomic analysis
- coupled with extreme phenotype sampling identified that lysophosphatidylcholines are
- associated with multisite musculoskeletal pain. Pain. 2020/08/25 ed 1o de fevereiro
- 663 de 2021;162(2):600–8.
- 664 38. Fujita N, Ishihara S, Michikawa T, Azuma K, Suzuki S, Tsuji O, et al. Potential
- association of metabolic and musculoskeletal disorders with lumbar intervertebral disc
- 666 degeneration: Cross-sectional study using medical checkup data. J Orthop Sci.
- 667 2019/06/10 ed maio de 2020;25(3):384-8.
- 668 39. Aroke EN, Powell-Roach KL. The Metabolomics of Chronic Pain Conditions: A
- 669 Systematic Review. Biol Res Nurs. 2020/07/16 ed outubro de 2020;22(4):458–71.
- 670 40. Ji RR, Donnelly CR, Nedergaard M. Astrocytes in chronic pain and itch. Nat
- 671 Rev Neurosci. 2019/09/21 ed novembro de 2019;20(11):667–85.

- 672 41. Wu X, Xiang H, Zhang G, Hu Y, wang yan, Chen B. A metabolic profiling
- analysis of degenerative intervertebral disc disease in a rabbit model via GC/TOF-MS.
- 674 2019; Disponível em: https://www.researchsquare.com/article/rs-7971/v1
- 675 42. Radek M, Pacholczyk-Sienicka B, Jankowski S, Albrecht L, Grodzka M, Depta
- A, et al. Assessing the correlation between the degree of disc degeneration on the
- Pfirrmann scale and the metabolites identified in HR-MAS NMR spectroscopy. Magn
- 678 Reson Imaging. 2015/12/29 ed maio de 2016;34(4):376–80.
- 679 43. Teraguchi M, Yoshimura N, Hashizume H, Muraki S, Yamada H, Oka H, et al.
- 680 Metabolic Syndrome Components Are Associated with Intervertebral Disc
- 681 Degeneration: The Wakayama Spine Study. PLoS One. 2016/02/04 ed
- 682 2016;11(2):e0147565.
- 683 44. Veras MA, Lim YJ, Kuljanin M, Lajoie GA, Urquhart BL, Seguin CA. Protocol
- 684 for parallel proteomic and metabolomic analysis of mouse intervertebral disc tissues.
- 585 JOR Spine. 2020/10/06 ed setembro de 2020;3(3):e1099.
- 686 45. Tang G, Han X, Lin Z, Qian H, Chen B, Zhou C, et al. Propionibacterium acnes
- 687 Accelerates Intervertebral Disc Degeneration by Inducing Pyroptosis of Nucleus
- Pulposus Cells via the ROS-NLRP3 Pathway. Oxid Med Cell Longev. 2021/02/20 ed
- 689 2021;2021:4657014.
- 690 46. Lin Y, Jiao Y, Yuan Y, Zhou Z, Zheng Y, Xiao J, et al. Propionibacterium acnes
- 691 induces intervertebral disc degeneration by promoting nucleus pulposus cell apoptosis
- 692 via the TLR2/JNK/mitochondrial-mediated pathway. Emerg Microbes Infect.
- 693 2018/01/13 ed 10 de janeiro de 2018;7(1):1.
- 694 47. Capoor MN, Ruzicka F, Sandhu G, Rollason J, Mavrommatis K, Ahmed FS, et
- al. Importance of Propionibacterium acnes hemolytic activity in human intervertebral
- 696 discs: A microbiological study. PLoS One. 2018/11/30 ed 2018;13(11):e0208144.
- 697 48. Albert HB, Kjaer P, Jensen TS, Sorensen JS, Bendix T, Manniche C. Modic
- 698 changes, possible causes and relation to low back pain. Med Hypotheses.
- 699 2008;70(2):361-8.
- 700 49. Ohtori S, Koshi T, Yamashita M, Yamauchi K, Inoue G, Suzuki M, et al.
- 701 Existence of pyogenic spondylitis in Modic type 1 change without other signs of
- 702 infection: 2-year follow-up. Eur Spine J. 2010/03/10 ed julho de 2010;19(7):1200–5.
- 703 50. Ritter PL, González VM, Laurent DD, Lorig KR. Measurement of pain using the
- visual numeric scale. J Rheumatol. março de 2006;33(3):574–80.

- 705 51. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals
- 706 EKB, et al. Assessment of pain. Br J Anaesth. julho de 2008;101(1):17–24.
- 707 52. Bagattini ÂM, Camey SA, Miguel SR, Andrade MV, de Souza Noronha KVM,
- 708 de C. Teixeira MA, et al. Electronic Version of the EQ-5D Quality-of-Life
- 709 Questionnaire: Adaptation to a Brazilian Population Sample. Value Health Reg Issues.
- 710 1o de dezembro de 2018;17:88–93.
- 711 53. Vigatto R. Alexandre NM, Correa Filho HR. Development of a Brazilian
- 712 Portuguese version of the Oswestry Disability Index: cross-cultural adaptation,
- 713 reliability, and validity. Spine Phila Pa 1976. 2007/02/17 ed 15 de fevereiro de
- 714 2007;32(4):481–6.
- 715 54. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
- sequence data. Bioinforma Oxf Engl. 10 de agosto de 2014;30(15):2114–20.
- 717 55. Lohse M, Bolger AM, Nagel A, Fernie AR, Lunn JE, Stitt M, et al. RobiNA: a
- 718 user-friendly, integrated software solution for RNA-Seq-based transcriptomics.
- 719 Nucleic Acids Res. julho de 2012;40 (Web Server issue):W622-627.
- 720 56. Shah H, Encheva V, Schmid O, Culak RA, Nasir P, Ines I, et al. Surface
- 721 Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry (SELDI-
- 722 TOF-MS): A Potentially Powerful Tool for Rapid Characterisation of Microorganisms.
- 723 In 2005. p. 57–95.
- 724 57. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a
- web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics.
- 726 22 de maio de 2015;16(1):169.
- 727 58. Urrutia J, Besa P, Campos M, Cikutovic P, Cabezon M, Molina M, et al. The
- 728 Pfirrmann classification of lumbar intervertebral disc degeneration: an independent
- 729 inter- and intra-observer agreement assessment. Eur Spine J. 2016/02/18 ed
- 730 setembro de 2016;25(9):2728–33.
- 731 59. Medronho R, Bloch K, Luiz R, Werneck G. Epidemiologia. Atheneu. São Paulo.
- 732 2009;

		STUDY PERIOD							
		Enrolment	Allocation	Post-allocation					Close-out
	TIMEPOINT**	Aug/22	Set/22	Oct/22	Dec/22	Feb/23	Apr/23	Jun/23	Aug/23
	ENROLMENT:								
	Eligibility screening	Х		х					
	Informed consent			X					
edRxiv prep	Clinical Survey	22277406; this version po	sted July 9, 2022. The cop	X yright holder f	or this preprin				
which was i	rint doi: https://doi.org/10.1101/2022.07.08 not certified by peer review) is the autho It is made availabl	/funder, who has granted e under a CC-BY 4.0 Inter	nedRxiv a license to displinational license.	ly the preprint	in perpetuity.				
	Allocation		Х						
	INTERVENTIONS:								
	Surgery			ļ		†			
	Sampling			ļ		\rightarrow			
	Sample Analysis			ļ			Ť		
	ASSESSMENTS:								
	List baseline variables	Х	х						
	Data processing				-			→	
	Publication preparation								х

^{*}Recommended content can be displayed using various schematic formats. See SPIRIT 2013 Explanation and Elaboration for examples from protocols.

**List specific timepoints in this row.

